BIOexpress
Biotronik, Inc. · Decision date Oct 16, 2026
What did the FDA approve?
The FDA record shows an approval decision dated 2026-10-16 for BIOexpress, listed as a dedicated interrogation-only device used for status checks of BIOTRONIK implantable pulse generators (IPGs, CRT-Ps), implantable cardioverter defibrillators (ICDs, CRT-Ds) and implantable cardiac monitors (ICMs). The supplement is identified as P950037/S289, a normal 180-day track filing whose stated reason is a change to design, components, specifications or material. The record does not specify which component, specification or material changed.
P950037/S289 is a supplement to the existing P950037 approval rather than a new approval of the whole system, and the record gives no manufacturing-notice detail. BIOexpress is described by category as an implantable pacemaker pulse-generator device under product code DXY in the Cardiovascular specialty. The reported interrogation-only purpose is the statement's own description, not independent evidence of safety or clinical effectiveness, and the record supplies no test data or clinical outcomes.
FDA approval order statement
BIOexpress, a dedicated interrogation-only device for status checks of BIOTRONIK implantable pulse generators (IPGs, CRT-Ps), implantable cardioverter defibrillators (ICDs, CRT-Ds) and implantable cardiac monitors (ICMs)
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 16, 2026
- FDA change category
- Change Design/Components/Specifications/Material
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P950037/S289
- Regulatory pathway
- PMA supplement
- Applicant
- Biotronik, Inc.
- Product code
- DXY
- Decision code
- APPR
- Decision date
- Oct 16, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: implantable pacemaker Pulse-generator.
- Applicant
- Biotronik, Inc.
- Product code
- DXY
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P950037. Subsequent supplements may change the device or its indications.
FDA decision timeline
P950037 · Original PMA
DROMOS DR/DR-A AND DROMOS SR/SR-B CARDIAC PACING SYSTEMS
P950037/S289 received
Application receipt date recorded by FDA.
P950037/S291 · Related supplement
PSW 2601.U, NEO 2601.U, Amvia Sky HF-T QP, Amvia Sky HF-T, Amvia Edge HF-T QP, Amvia Sky DR-T, Amvia Sky SR-T, Amvia Edg
P950037/S279 · Related supplement
Edora 8 DR-T 407145, Evity 8 DR-T 407146, Enitra 8 DR-T 407147, Enticos 8 DR-T 407148, Evity 6 DR-T 407149, Enitra 6 DR-
P950037/S296 · Related supplement
Edora 8 DR-T 407145; Evity 8 DR-T 407146; Enitra 8 DR-T 407147; Enticos 8 DR-T 407148; Evity 6 DR-T 407149; Enitra 6 DR-
P950037/S298 · Related supplement
Edora 8 DR-T, Evity 8 DR-T, Enitra 8 DR-T, Evity 6 DR-T, Enitra 6 DR-T, Edora 8 DR, Enitra 6 DR, Enticos 4 DR, Enticos
P950037/S289 · FDA decision
Normal 180 Day Track
P950037/S299 · Related supplement
Edora 8 DR-T, Evity 8 DR-T, Enitra 8 DR-T, Enticos 8 DR-T, Evity 6 DR-T, Enitra 6 DR-T, Edora 8 DR, Enitra 6 DR, Edora 8
P950037/S300 · Related supplement
Amvia Sky DR-T, Amvia Sky SR-T; Amvia Edge DR-T, Amvia Edge SR-T; Solvia Rise DR-T, Solvia Rise SR-T; Amvia Sky HF-T QP,
Timeline entries are records held by MedtechLedger for P950037. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P950037
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biotronik, Inc. | PMA approval | Oct 11, 1996 | FDA | |
| Biotronik, Inc. | PMA supplement | Sep 17, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Sep 25, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 9, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 13, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 22, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 28, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Biotronik, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6024 Jean Rd., Lake Oswego, OR, 97035
Sources and methodology
- Original FDA record: P950037/S289
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




